# Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers

> **NCT03654989** · PHASE1,PHASE2 · TERMINATED · sponsor: **University Hospital, Grenoble** · enrollment: 4 (actual)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **DRUG:** Treprostinil iontophoresis
- **DEVICE:** Remodulin® placebo iontophoresis

## Key facts

- **NCT ID:** NCT03654989
- **Lead sponsor:** University Hospital, Grenoble
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-28
- **Primary completion:** 2021-12-07
- **Final completion:** 2021-12-07
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** recruitment difficulties
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03654989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03654989, "Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03654989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*